Presentation highlights APOE genotype testing via a quick fingertip prick validated in Niki BioSolutions’ CLIA-certified laboratory and recently approved by the New York State Department of Health NEW HAVEN, CT, and
NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use NEW HAVEN, CT and PRINCETON, NJ, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Niki
Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer’s clinical research network PRINCETON, NJ, NEW HAVEN, CT and ORLANDO, FL, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions,
Company’s blood-based microRNA biomarker panel is designed to support monitoring of disease progression and treatment response in Rett syndrome Access the "Rett Research Tool Belt" at
Plasma-based APOE genotyping to add genetic risk data to a diverse, deeply characterized Alzheimer’s biomarker cohort PRINCETON, N.J., and NEW HAVEN, Conn., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc.
NEW HAVEN, CT and PRINCETON, NJ, Sept. 25, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ:NIKI), a life sciences company focused on addressing unmet medical needs and providing high-quality genomic and
Advanced multi-omics data analysis and biostatistical expertise to sharpen target and biomarker decisions across the platform PRINCETON, N.J., and NEW HAVEN, Conn., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Niki
Live company presentation will take place on September 14 at 10:30 AM ET NEW HAVEN, CT and PRINCETON, NJ, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc. (NASDAQ:NIKI), a life sciences company focused on
Partnership Expands Access to Clinically Critical Genetic Testing in Support of Leading Research Programs NEW HAVEN, CT and PRINCETON, NJ, July 23, 2026 (GLOBE NEWSWIRE) -- Niki BioSolutions, Inc., a clinical-stage
